)
Bolt Biotherapeutics (BOLT) investor relations material
Bolt Biotherapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net loss narrowed to $4.4M from $7.1M YoY as operating expenses declined; collaboration revenue was $0.
The October 23 Prana acquisition and $120M private placement shifted development focus to PRA-216 and the INSPIRE multispecific pipeline.
Financial highlights
Q3 collaboration revenue was $0 versus $2.2M; 9M revenue was $31K versus $5.2M.
Q3 operating expenses were $4.7M versus $9.9M; 9M expenses were $20.7M versus $34.2M, including a $0.8M impairment charge in 2026.
Q3 operating loss was $4.7M versus $7.7M; net loss was $4.4M versus $7.1M. 9M operating loss was $20.7M versus $29.0M; net loss was $19.5M versus $26.7M.
Q3 basic and diluted loss per share was $2.25 versus $3.72; 9M loss per share was $10.09 versus $13.94.
Q3 R&D expense fell to $2.2M from $6.5M and G&A to $2.5M from $3.3M, reflecting lower program activity, headcount and personnel costs, restructuring and R&D tax incentives.
Outlook and guidance
PRA-216 is in Phase 2 for asthma, COPD and atopic dermatitis; a fourth Phase 2 study in eosinophilic esophagitis is planned.
Initial PRA-216 Phase 2 data and proof-of-concept data across four studies are expected beginning in 2Q 2027; a second wholly owned INSPIRE program is expected to enter clinical testing and generate initial data in 2H 2027.
Based on the operating plan and October financing, funding is expected into 2028, subject to Series D conversion and successful delivery of common shares.
Significant operating losses and R&D spending are expected to continue; future funding needs depend on clinical progress, development costs and access to financing or partnerships.
- Reverse merger adds INSPIRE and funds PRA-216’s 2027 readouts with $120 million upfront.BOLT
M&A announcement - BDC-4182 trial advances as cash runway extends into Q1 2027 amid ongoing losses and capital needs.BOLT
Q2 2026 - Net loss narrowed as BDC-4182 advances, but cash runway is limited and capital needs are urgent.BOLT
Q1 2026 - Virtual meeting to elect directors and ratify auditor, with Board recommending all proposals.BOLT
Proxy filing - Stockholders will vote on director elections and auditor ratification at a virtual annual meeting.BOLT
Proxy filing - BDC-4182 Phase 1 progresses, losses narrow, and cash runway extends into 2027.BOLT
Q4 2025 - Key votes include director elections, auditor ratification, and a reverse stock split for Nasdaq compliance.BOLT
Proxy Filing - Next-gen immunotherapies advance toward key clinical milestones, backed by strong financials.BOLT
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Next-gen ISACs advance toward key clinical milestones, aiming for broader efficacy and durability.BOLT
Morgan Stanley 22nd Annual Global Healthcare Conference
)
)
)
)
)
)
)
)